In the preceding three months, 4 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.25, along with a high estimate of $87.00 and a low estimate of $65.00. Experiencing a 11.54% decline, the current average is now lower than the previous average price target of $87.33.

Understanding Analyst Ratings: A Comprehensive Breakdown

A comprehensive examination of how financial experts...